GlassScriptPhysician profile
Devin Karl Loewenstein
NPI 1912325366
$4,327.32
in general payments reported to CMS, 2019-2025
26 companies · $1,827 in 2025
The $1,827 reported for 2025 was more than what 82% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $245 · 2023: $694 · 2024: $1,562 · 2025: $1,827.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,083.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,082.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $613.54 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $579.58 | 2023-2025 | Jardiance |
| Novo Nordisk INC | $575.40 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $399.68 | 2023-2025 | Opsumit, Uptravi, Opsynvi |
| Astrazeneca Pharmaceuticals LP | $373.99 | 2023-2025 | Farxiga |
| Amgen INC. | $272.05 | 2023-2025 | Repatha, Repatha |
| Pfizer INC. | $245.70 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $201.38 | 2023-2025 | Camzyos, Eliquis |
| Medtronic, INC. | $133.54 | 2023-2025 | Linq II, Corevalve Evolut R |
| Bridgebio Pharma, INC. | $125.03 | 2025 | Attruby |
| Sanofi-Aventis U.S. LLC | $115.23 | 2019 | |
| Surgical Specialties Corporation (US), INC. (Dba Corza Medical) | $113.68 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $94.24 | 2024 | Arcalyst |
| Lilly USA, LLC | $87.20 | 2024-2025 | Mounjaro, Zepbound |
| Abiomed | $75.17 | 2024 | Impella |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $71.52 | 2025 | Onpattro |
| Abbott Laboratories | $47.58 | 2025 | Thoratec Heartmate 3 Lvas Implant Kit |
| Lantheus Medical Imaging, INC. | $38.42 | 2024 | |
| Ethicon US, LLC | $29.12 | 2025 | Evarrest, Surgiflo Hemostatic Matrix, Surgicel Nu-Knit |
| Chiesi USA, INC. | $23.92 | 2023 | Cleviprex, Kengreal |
| Lexicon Pharmaceuticals, INC. | $22.46 | 2024 | |
| Vital Connect, INC | $20.56 | 2025 | Vitalpatch Rtm |
| Merck Sharp & Dohme LLC | $19.20 | 2025 | Verquvo |
| Scpharmaceuticals INC. | $17.97 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.28 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $13.88 | 2025 | Opsumit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devin Loewenstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.